Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients.

ABSTRACT:

Background

The clinical course of cutaneous melanoma (CM) can differ significantly for patients with identical stages of disease, defined clinico-pathologically, and no molecular markers differentiate patients with such a diverse prognosis. This study aimed to define the prognostic value of whole genome DNA methylation profiles in stage III CM.

Methods

Genome-wide methylation profiles were evaluated by the Illumina Human Methylation 27 BeadChip assay in short-term neoplastic cell cultures from 45 stage IIIC CM patients. Unsupervised K-means partitioning clustering was exploited to sort patients into 2 groups based on their methylation profiles. Methylation patterns related to the discovered groups were determined using the nearest shrunken centroid classification algorithm.

SUBMITTER: Sigalotti L 

PROVIDER: S-EPMC3539917 | biostudies-literature | 2012 Sep

REPOSITORIES: biostudies-literature